166P - Mutations of KRAS/NRAS/BRAF in cetuximab-resistant metastatic CRC patients

Date 19 December 2015
Event ESMO Asia 2015 Congress
Session Poster presentation 1
Topics Anticancer Agents
Colon and Rectal Cancer
Pathology/Molecular Biology
Basic Scientific Principles
Biological Therapy
Presenter Yen-Jung Lu
Citation Annals of Oncology (2015) 26 (suppl_9): 42-70. 10.1093/annonc/mdv523
Authors Y. Lu1, T.K. Thiam1, S.J. Chen1, H.C. Hsu2
  • 1Act Genomics, ACT Genomics, 11494 - Taipei/TW
  • 2Division Of Hematology‑oncology, Chang Gung Memorial Hospital-Linkou, 333 - Taoyuan/TW



Although patients with metastatic colorectal cancer (mCRC) bearing KRAS-exon2-wild-type could benefit from cetuximab treatment, ∼ 45% of these patients were refractory to such a therapy. This study aims to identify additional genetic markers that can enhance the prediction of the cetuximab treatment response.


53 mCRC patients with wild-type KRAS exon2 were treated with cetuximab/irinotecan-based chemotherapy in first-line or third-line setting. Formalin-fixed paraffin-embedded samples obtained from primary tumor of all subjects were analyzed for the mutational status of 10 genes in the EGFR pathway using next-generation sequencing technology.


We detected KRAS (exon 3 and 4) mutations in 5 patients, NRAS mutations in 4 patients, and BRAF mutations in 6 patients. Except for 1 patient with an NRAS mutation who was a responder, all other patients harboring KRAS, NRAS, or BRAF mutations are non-responders, indicating the predictive role of these genetic mutations for poor cetuximab responsivness. The Kaplan-Mirer analysis revealed that patients with KRAS or BRAF mutations have a significantly shorter progress-free survival.


Our results suggest that genetic testing for KRAS in combination with NRAS and BRAF provides a stronger predictive power and should be implemented to improve the response rate of cetuximab for mCRC patients.

Clinical trial identification


All authors have declared no conflicts of interest.